Mirae Asset Global Investments Co. Ltd. Sells 546 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Mirae Asset Global Investments reduced its stake in Thermo Fisher Scientific by 0.9%, selling 546 shares, leaving them with 58,823 shares valued at approximately $23.85 million.
• Several hedge funds have increased their holdings in Thermo Fisher, with Brighton Jones LLC boosting its stake by 28.9% and Retirement Planning Group LLC by 41.6% during the latest quarter.
• Thermo Fisher Scientific reported a 2.9% year-over-year revenue increase to $10.86 billion in its most recent earnings report, surpassing analyst expectations; it also announced a quarterly dividend of $0.43.

Mirae Asset Global Investments Co. Ltd. trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,823 shares of the medical research company's stock after selling 546 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Thermo Fisher Scientific were worth $23,850,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in TMO. Brighton Jones LLC lifted its stake in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after buying an additional 988 shares during the period. Revolve Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after buying an additional 20 shares during the period. Apella Capital LLC lifted its stake in Thermo Fisher Scientific by 10.5% during the first quarter. Apella Capital LLC now owns 600 shares of the medical research company's stock worth $272,000 after purchasing an additional 57 shares during the period. Retirement Planning Group LLC lifted its stake in Thermo Fisher Scientific by 41.6% during the first quarter. Retirement Planning Group LLC now owns 640 shares of the medical research company's stock worth $318,000 after purchasing an additional 188 shares during the period. Finally, Breakwater Capital Group lifted its stake in Thermo Fisher Scientific by 47.0% during the first quarter. Breakwater Capital Group now owns 960 shares of the medical research company's stock worth $478,000 after purchasing an additional 307 shares during the period. Institutional investors own 89.23% of the company's stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on TMO. Raymond James Financial restated an "outperform" rating and set a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. HSBC restated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Finally, Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $585.37.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $543.88 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market cap of $205.37 billion, a P/E ratio of 31.46, a P/E/G ratio of 2.85 and a beta of 0.77. The firm has a 50 day simple moving average of $482.58 and a 200 day simple moving average of $447.76. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter last year, the business posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.